Evidence map›Paper›PMID 33417200›Full record

ArticleJournal of gastrointestinal cancer2022

Frequent Downregulation and Promoter Hypermethylation of DLC1: Relationship with Clinical Outcome in Gallbladder Cancer.

Deepika Singh, Amisha Bharti, Dipanjan Biswas, Mallika Tewari, Amrita Ghosh Kar, Mumtaz Ahmed Ansari, Sunita Singh, Gopeshwar Narayan

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deepika SinghCancer Genetics Laboratory, Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, 221005, India.
Amisha BhartiDepartment of Zoology, Mahila Mahavidyalaya, Banaras Hindu University, Varanasi, 221005, India.
Dipanjan BiswasDepartment of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India.
Mallika TewariDepartment of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India.
Amrita Ghosh KarDepartment of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India.
Mumtaz Ahmed AnsariDepartment of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India.
Sunita SinghDepartment of Zoology, Mahila Mahavidyalaya, Banaras Hindu University, Varanasi, 221005, India.
Gopeshwar NarayanCancer Genetics Laboratory, Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, 221005, India. gnarayan@bhu.ac.in.ORCID http://orcid.org/0000-0001-5851-9997

Funding

University Grants Commission 43-349/2014(SR)
6 · The paper itself

Abstract

introductionDown regulation of DLC1 is associated with poor prognosis in many cancers, however, its role in gallbladder cancer (GBC) is still unclear. In present study, we investigated the expression profile and promoter methylation status of DLC1.

methodsExpression profiles of DLC1 in 55 GBC and their paired adjacent control samples were analyzed through real time RT-PCR and immunohistochemistry. The mRNA data was correlated with clinico-pathological parameters. Promoter hypermethylation was analyzed through MSP.

resultsDLC1 shows downregulation in 76.4%, upregulation in 10.9% whereas no change in 12.7% of GBC samples. Its underexpression shows significant correlation with tumor grade and nodal spread. IHC shows cytoplasmic expression of DLC1 in normal as well as tumor samples. IHC result was concordant to mRNA result. Samples having downregulated DLC1 expression show heterozygous methylation in 83.3% of samples and homozygous methylation in 9.5% of samples whereas 7% of samples have no methylation. Kaplan-Meier analysis shows patient with decreased mRNA of DLC1 have significant low mean survival compared to patients with higher mRNA expression of DLC1.

conclusionOur findings suggested that dysregulated expression of DLC1 and its hypermethylation may be one of the events playing roles in tumorigenesis of GBC and may serve as a potential target for development of future GBC gene therapy.

Indexed as

Gallbladder NeoplasmsGTPase-Activating ProteinsTumor Suppressor ProteinsCell Line, TumorDNA MethylationDown-RegulationGene Expression Regulation, NeoplasticHumansPrognosisPromoter Regions, GeneticRNA, MessengerDLC1 protein, humanGTPase-Activating ProteinsRNA, MessengerTumor Suppressor ProteinsDeleted in liver cancer-1Gallbladder cancerImmunohistochemistryMethylation-specific PCRPrognostic marker

Identifiers

PMID33417200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.